FDA advisory panel to review Remoxy and Embeda
Executive Summary
FDA's Anesthetic and Life Support Drugs and Drug Safety and Risk Management advisory committees will review two abuse-resistant formulations of opioids for chronic pain Nov. 13 and 14: Pain Therapeutics/King Pharmaceuticals' Remoxy XRT (oxycodone hydrochloride controlled-release) and Alpharma Pharmaceuticals' Embeda (morphine sulfate extended-release with sequestered naltrexone hydrochloride). Risk management plans could play a large role in the votes, as indicated by the fate of Cephalon's analgesic Fentora (buccal fentanyl), earlier this year (1"The Pink Sheet" DAILY, Sept. 15, 2008)
You may also be interested in...
Fentora Expansion Awaits REMS Evaluation
“Complete response” letter calls for Cephalon to “demonstrate” that risk management works before Fentora can add new indication.
California Court’s Inaction On TiO2 Prop 65 First Amendment Case Breeds New Lawsuits
The Personal Care Products Council seeks to stem the rising tide of titanium dioxide Proposition 65 lawsuits, requesting that a California court prohibit the state’s Attorney General and private enforcers from filing and/or prosecuting new suits against cosmetics companies failing to warn about potential TiO2 exposure.
Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer
Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025. It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.